Conventional Dendritic Cells – Ecology, Diversity, and Function
The project aims to explore the diverse roles of conventional dendritic cell subsets in T cell activation during different immune responses to enhance cancer therapies and vaccine efficacy.
Projectdetails
Introduction
Effective T cell responses are critical for the efficacy of vaccination and cancer immunotherapy; therefore, the manipulation of conventional dendritic cells (cDCs) offers great potential for improved therapies as these cells play a key role in the activation and regulation of T cell function.
Background
However, cDCs are a diverse group of cells whose function is incompletely understood. Previous attempts at targeting cDCs therapeutically have been underwhelming, perhaps as a result of not targeting the right cell subset specifically.
Objectives
The goal of this proposal is to:
- Reveal the functional properties of the different cDC lineages during type 1 and type 2 immunity.
- Understand how the ecology of cDC subsets is regulated to meet the functional demands of tissues undergoing different types of inflammation.
Research Approach
I propose that studying the cDC subsets that:
- Enhance cytotoxic T cell responses against viruses in type 1 immunity.
- Enhance parasite clearance and tissue repair in type 2 immunity against nematodes.
This will help to identify those cDC subsets that need to be either triggered or inhibited to improve tumor control.
Methodology
Therefore, we will:
- Use well-defined models of type 1 and type 2 immunity to reveal the diversity of these cells during inflammation.
- Generate new mouse models to target cDC subsets specifically to study their functional properties and to reveal how these functional properties are instructed.
Inter-Organ Communication
In this regard, we will address how subset specification is regulated distally by a novel inter-organ communication axis (lung-bone marrow) that could tune the host immune system to ever-evolving challenges.
Proof of Concept
Finally, as a proof of concept, we will use transplantable and orthotopic cancer models to unravel beneficial and detrimental cDC subsets in the immune response against cancer.
Conclusion
cDCFun will open new avenues for the design of better vaccines and immunotherapies that harness the functional properties of specific subsets of cDCs.
Financiële details & Tijdlijn
Financiële details
Subsidiebedrag | € 1.796.125 |
Totale projectbegroting | € 1.796.125 |
Tijdlijn
Startdatum | 1-1-2024 |
Einddatum | 31-12-2028 |
Subsidiejaar | 2024 |
Partners & Locaties
Projectpartners
- FUNDACAO D. ANNA DE SOMMER CHAMPALIMAUD E DR. CARLOS MONTEZ CHAMPALIMAUDpenvoerder
Land(en)
Vergelijkbare projecten binnen European Research Council
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
A novel immuno-oncolytic virus-based dendritic cell therapeutic cancer vaccineDCanVAX aims to create a novel oncolytic virus-based dendritic cell vaccine to enhance immune responses against solid tumors by utilizing a complete tumor antigen library for personalized therapy. | ERC Proof of... | € 150.000 | 2024 | Details |
Dissecting the context-specificity of genetic immune regulation in plasmacytoid dendritic cellsThe project aims to uncover the genetic regulation and functional diversity of plasmacytoid dendritic cells to explain variability in antiviral responses and autoimmune diseases across diverse populations. | ERC Starting... | € 1.499.235 | 2023 | Details |
Neoantigen Identification with Dendritic Cell ReprogrammingThe NeoIDC project aims to revolutionize cancer immunotherapy by using cDC1 reprogramming to identify immunogenic neoantigens and TCRs for developing effective vaccines and adoptive T cell therapies. | ERC Proof of... | € 150.000 | 2023 | Details |
Deciphering Antigen-Specific Circuits Orchestrating Tolerance.This project aims to uncover the cellular interactions governing peripheral regulatory T cell responses to gut microbes, enhancing understanding of tolerance mechanisms for treating inflammation-related conditions. | ERC Starting... | € 2.175.000 | 2024 | Details |
C- and N-terminal Epitope Conjugate immune Cell Targeted VaccinesCNECT-VAX aims to validate a novel cancer vaccine platform using nanobodies for targeted dendritic cell activation to enhance immune responses and improve treatment efficacy. | ERC Proof of... | € 150.000 | 2022 | Details |
A novel immuno-oncolytic virus-based dendritic cell therapeutic cancer vaccine
DCanVAX aims to create a novel oncolytic virus-based dendritic cell vaccine to enhance immune responses against solid tumors by utilizing a complete tumor antigen library for personalized therapy.
Dissecting the context-specificity of genetic immune regulation in plasmacytoid dendritic cells
The project aims to uncover the genetic regulation and functional diversity of plasmacytoid dendritic cells to explain variability in antiviral responses and autoimmune diseases across diverse populations.
Neoantigen Identification with Dendritic Cell Reprogramming
The NeoIDC project aims to revolutionize cancer immunotherapy by using cDC1 reprogramming to identify immunogenic neoantigens and TCRs for developing effective vaccines and adoptive T cell therapies.
Deciphering Antigen-Specific Circuits Orchestrating Tolerance.
This project aims to uncover the cellular interactions governing peripheral regulatory T cell responses to gut microbes, enhancing understanding of tolerance mechanisms for treating inflammation-related conditions.
C- and N-terminal Epitope Conjugate immune Cell Targeted Vaccines
CNECT-VAX aims to validate a novel cancer vaccine platform using nanobodies for targeted dendritic cell activation to enhance immune responses and improve treatment efficacy.
Vergelijkbare projecten uit andere regelingen
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Functional chemical reprogramming of cancer cells to induce antitumor immunityThe RESYNC consortium aims to revolutionize cancer immunotherapy by reprogramming cancer cells into antigen-presenting dendritic cells using small molecules for personalized and safer treatments. | EIC Pathfinder | € 2.966.695 | 2024 | Details |
Functional chemical reprogramming of cancer cells to induce antitumor immunity
The RESYNC consortium aims to revolutionize cancer immunotherapy by reprogramming cancer cells into antigen-presenting dendritic cells using small molecules for personalized and safer treatments.